Tenax Therapeutics, Inc. (TENX)

NASDAQ: TENX · IEX Real-Time Price · USD
5.01
+0.42 (9.15%)
At close: Mar 1, 2024, 4:00 PM
5.04
+0.03 (0.60%)
After-hours: Mar 1, 2024, 7:57 PM EST
9.15%
Market Cap 8.85M
Revenue (ttm) n/a
Net Income (ttm) -7.03M
Shares Out 1.77M
EPS (ttm) -95.20
PE Ratio n/a
Forward PE 0.30
Dividend n/a
Ex-Dividend Date n/a
Volume 548,995
Open 4.60
Previous Close 4.59
Day's Range 4.40 - 5.07
52-Week Range 3.77 - 64.40
Beta 2.45
Analysts Strong Buy
Price Target 30.00 (+498.8%)
Earnings Date Apr 1, 2024

About TENX

Tenax Therapeutics, Inc. develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension. It develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The company was formerly known as... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1967
Employees 7
Stock Exchange NASDAQ
Ticker Symbol TENX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to one analyst, the rating for TENX stock is "Strong Buy" and the 12-month stock price forecast is $30.0.

Price Target
$30.0
(498.80% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Tenax Therapeutics Announces Oral Presentation of Levosimendan for the Treatment of PH-HFpEF at THT 2024

Dr. Sanjiv Shah, a renowned, global expert in the treatment of HFpEF and PH-HFpEF, will present data highlighting the use of levosimendan for the treatment of pulmonary hypertension due to heart failu...

3 days ago - GlobeNewsWire

Tenax Therapeutics Announces Global License Amendment that Significantly Expands Rights to Levosimendan

CHAPEL HILL, N.C., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX), a Phase 3, development-stage pharmaceutical company focused on identifying, developing and commercializing...

12 days ago - GlobeNewsWire

Tenax Therapeutics Announces Pricing of Approximately $9 Million Public Offering

CHAPEL HILL, N.C., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products that ad...

24 days ago - GlobeNewsWire

Tenax Therapeutics Enrolls First Patient in Phase 3 LEVEL Study Evaluating TNX-103 (Oral Levosimendan) for the Treatment of Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

Over 40 sites (U.S. and Canada) have agreed to participate in the LEVEL study LEVEL is a randomized, controlled Phase 3 trial of 152 patients, and will recruit patients primarily from leading research...

25 days ago - GlobeNewsWire

Biotech stock Tenax Therapeutics more than doubled on Tuesday

Tenax Therapeutic Inc (NASDAQ: TENX) opened nearly 150% up this morning after receiving approval for a patent application. Tenax Therapeutics stock rallies ahead of earnings The U.S. Patent and Tradem...

26 days ago - Invezz

Tenax Therapeutics Announces USPTO Grants Notice of Allowance for U.S. Patent Application, Significantly Broadening IP Protection for Use of Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

Once granted, this patent will: provide U.S. intellectual property (IP) protection until December 2040, and may qualify for additional U.S. patent term extension (PTE) beyond 2040 broaden IP protectio...

26 days ago - GlobeNewsWire

Tenax Therapeutics Announces Reverse Stock Split

CHAPEL HILL, N.C., Dec. 29, 2023 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products that ad...

2 months ago - GlobeNewsWire

Tenax Therapeutics Announces Professor Javed Butler, M.D., M.P.H, M.B.A.

CHAPEL HILL, N.C., Nov. 17, 2023 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products that ad...

3 months ago - GlobeNewsWire

Tenax Therapeutics Announces FDA Clearance of IND for TNX-103 (oral levosimendan) for the Treatment of Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF), Initiation of Phase 3 sites expected 2023

CHAPEL HILL, N.C., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products that ad...

3 months ago - GlobeNewsWire

Tenax Therapeutics Issued U.S. Patent for Oral Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

CHAPEL HILL, N.C., July 19, 2023 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products that ad...

8 months ago - GlobeNewsWire

Tenax Therapeutics Achieves Major Milestone as USPTO Grants Notice of Allowance for U.S. Patent Application Covering Use of Oral Levosimendan (TNX-103) in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

CHAPEL HILL, N.C., May 31, 2023 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products that add...

9 months ago - GlobeNewsWire

Tenax Therapeutics Provides 2023 Business Update

CHAPEL HILL, N.C., April 12, 2023 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products that a...

11 months ago - GlobeNewsWire

Tenax Announces Issuance of U.S. Patent Covering Use of IV Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

CHAPEL HILL, N.C., March 22, 2023 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products that a...

1 year ago - GlobeNewsWire

Tenax Therapeutics Announces Pricing of Approximately $15.6 Million Public Offering

CHAPEL HILL, N.C., Feb. 03, 2023 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products that ad...

1 year ago - GlobeNewsWire

Tenax Granted Notice of Allowance for U.S. Patent Application Covering Use of IV Levosimendan in Pulmonary Hypertension with Heart Failure and Preserved Ejection Fraction (PH-HFpEF)

CHAPEL HILL, N.C., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products that ad...

1 year ago - GlobeNewsWire

Positive Data Presented at HFSA Annual Meeting Demonstrate Effects of Oral Levosimendan in Patients with Pulmonary Hypertension and Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

MORRISVILLE, N.C., Oct. 10, 2022 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing, and commercializing products that a...

1 year ago - GlobeNewsWire

Tenax Therapeutics Announces the Evaluation of Strategic Alternatives

MORRISVILLE, N.C., Sept. 15, 2022 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products that a...

1 year ago - GlobeNewsWire

Tenax Therapeutics Announces Successful Comparative Pharmacokinetic Study of TNX-201 for the Treatment of Pulmonary Arterial Hypertension

MORRISVILLE, N.C.--(BUSINESS WIRE)--Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascu...

1 year ago - Business Wire

Tenax Therapeutics Announces $8 Million PIPE Offering Priced At-the-Market under Nasdaq Rules

MORRISVILLE, N.C.--(BUSINESS WIRE)--Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascu...

1 year ago - Business Wire

Tenax Therapeutics Reports Fiscal Year 2021 Results and Provides Business Update

MORRISVILLE, N.C.--(BUSINESS WIRE)--Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascu...

2 years ago - Business Wire

Tenax Therapeutics Announces Two Presentations at Upcoming American College of Cardiology Scientific Sessions

MORRISVILLE, N.C.--(BUSINESS WIRE)--Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascu...

2 years ago - Business Wire

Tenax Therapeutics Appoints Robyn Hunter to the Board of Directors

MORRISVILLE, N.C., Jan. 31, 2022 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing, and commercializing products that a...

2 years ago - GlobeNewsWire

Tenax Therapeutics Granted U.S. Patent for the Subcutaneous Use of Levosimendan (TNX-102)

Provides Broad Coverage for Use of TNX-102 for the Treatment of Human Subjects  with Any Health Condition

2 years ago - GlobeNewsWire

Tenax Therapeutics Provides Update on TNX-102, TNX-103 and TNX-201 Clinical Programs

Receives a Notice of Allowance of Multiple Patent Claims for TNX-102 (subcutaneous levosimendan)

2 years ago - GlobeNewsWire

Tenax Therapeutics Reports Third Quarter 2021 Results and Provides Business Update

MORRISVILLE, N.C.--(BUSINESS WIRE)--Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascu...

2 years ago - Business Wire